WuXi AppTec Pays $135 Million to Acquire Oxgene, a Gene Therapy CDMO
publication date: Mar 2, 2021
WuXi AppTec, a China-global CRO/CMO, paid $135 million to acquire Oxgene, a UK CDMO that develops scaleable gene technologies to develop cell and gene therapies. Previously, WuXi's gene therapy unit licensed Oxgene's novel TESSA technology for adeno-associated viral (AAV) manufacturing and XLenti stable solutions. WuXi found the technology a big improvement over the competition and wanted to invest in Oxgene, but ended up acquiring the entire company. Oxgene will become part of WuXi Advanced Therapies, WuXi's year-old cell and gene therapy Contract Testing, Development and Manufacturing Organization unit. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.